Philip K Liu

20080118440, May 22, 2008

Aug 23, 2005

11/574160

Philip Kuocherng Liu - Winchester MA, US
Young Ro Kim - Lynn MA, US
Bruce R. Rosen - Lexington MA, US
Christina Huang Liu - Winchester MA, US

THE GENERAL HOSPITAL CORPORATION - Boston MA

A61K 49/00
A61P 43/00

424 935

A reporter conjugate for non-invasive imaging of gene expression in vivo is disclosed. The conjugate includes a targeting nucleic acid linked to a contrast agent, such as a paramagnetic label that can be used with magnetic resonance imaging (MRI). The targeting nucleic acid can be an anti-sense strand that hybridizes to a portion of a messenger RNA encoded by the gene whose expression is to be imaged. In some embodiments, the contrast agent is a chelated metal such as gadolinium or dysprosium. The invention also features methods to image gene expression in various tissues, including the brain.

20100239504, Sep 23, 2010

Jul 17, 2008

12/669413

Philip Kuocherng Liu - Winchester MA, US
Christina Huang Liu - Winchester MA, US

The General Hospital Corporation - Boston MA

A61K 49/12
A61K 31/7088
C07H 21/04

424 935, 514 44 R, 536 231, 428402

Reporter conjugates for non-invasive in vivo detection, e.g., imaging, of expression or activity of nucleic acid binding proteins are disclosed. The conjugates include a targeting nucleic acid linked to a reporter group, e.g., a contrast agent, such as a paramagnetic label that can be used with magnetic resonance imaging. The targeting nucleic acid can be a double-stranded nucleic acid that binds to the nucleic acid binding protein the expression of which is to be imaged. In some embodiments, the contrast agent is a chelated metal such as gadolinium or dysprosium. The invention also features methods to image protein expression in various tissues, including the brain, and therapeutic methods.

20100310473, Dec 9, 2010

Jul 30, 2008

12/671283

Philip K. Liu - Winchester MA, US
Christina H. Liu - Winchester MA, US

THE GENERAL HOSPITAL CORPORATION - Boston MA

A61K 49/18
A61K 31/7088
A61K 31/7105
A61P 25/28

424 9323, 514 44 R, 424 91, 424 93, 424 932, 977773, 977906, 977916, 977927, 977930

It is disclosed here that nucleic acid-based agents can be delivered to the brain of a human or non-human animal having a leakage in the blood brain barrier by administering the agents through the eye. Brain tissues and cells can be imaged in vivo (e.g., by magnetic resonance imaging) by linking a contrast agent to a targeting nucleic acid that can hybridize to a target nucleic acid located at the brain site to be imaged and administering the contrast agentltargeting nucleic acid conjugate through the eye. Similarly, a nucleic acid based drug (e.g., as an antisense nucleic acid or a therapeutic agent linked to a targeting nucleic acid that can hybridize to a target nucleic located at a disease site in the brain) can be administered through the eye to treat a brain disease.

20110129421, Jun 2, 2011

Jul 17, 2008

12/669426

Philip Kuocherng Liu - Winchester MA, US
Christina Huang Liu - Winchester MA, US

The General Hospital Corporation - Boston MA

A61K 49/00
A61K 31/7088
A61P 35/00
A61P 31/04
A61P 31/18
B32B 5/16

424 91, 514 44 R, 428402

A reporter conjugate for non-invasive detection (e.g., imaging) of matrix metalloprotease (MMP) gene expression in vivo is disclosed. The conjugate includes a targeting nucleic acid linked to a contrast agent, such as a paramagnetic label that can be used with magnetic resonance (MR) imaging. The targeting nucleic acid can be an antisense strand that hybridizes to a portion of a messenger RNA encoded by the gene whose expression is to be imaged. In some embodiments, the contrast agent is a chelated metal such as gadolinium or dysprosium. The invention also features methods to detect MMP gene expression in various tissues, including the brain.

20160263253, Sep 15, 2016

Nov 14, 2014

15/036512

- Boston MA, US
Philip K. LIU - Winchester MA, US

A61K 49/12
C12N 15/113
C12N 7/00
A61K 49/18
A61K 47/48

We have developed a model system of HIV reservoirs in neural cells by generating chimeric phosphorothioate-modified oligodeoxynucleotides (sODN) that specifically interact with neural cell DNA or RNA, and that further comprise a sequence of the HIV genome. In particular, we have conjugated the chimera sODN to a delivery vehicle (e.g. a superparamagnetic iron oxide nanoparticle (SPIO)) and have demonstrated specific delivery to neural cells, in vitro and in vivo. These model systems can be used to screen for agents that specifically target latent viral infection. In particular, using the model system, we have developed suicide MRI contrast agents that can be used to reduce the number of neural cells which harbor the virus, also provided herein. Our model system is translatable to other latent viruses as well.